Grey cells with bold font represent findings associated with potential clinical benefit for a particular treatment regimen. None of the 12 patients whose HER2 levels were tested by IHC was found to be HER2 positive.
Marker
Threshold (marker intensity/percentage) Androgen Receptor (AR) = 0+ or <10% or 1+ and 10% c- KIT Grey cells with bold font represent findings associated with potential clinical benefit for a particular treatment regimen. None of the 12 patients whose HER2 levels were tested by IHC was found to be HER2 positive.
ACC, adenoid cystic carcinomas; AR, androgen receptor; ASNS, asparagine synthetase; CMI, Caris Molecular Intelligence; DCK, deoxycytidine kinase; EGFR, epidermal growth factor receptor; EPHA2, erythropoietin-producing hepatocellular receptor tyrosine kinase class A2; ER, estrogen receptor; ERCC, excision repair cross-complementation; ESR1, estrogen receptor 1; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; Int, intermediate; MGMT, O-6-methylguanine-DNA methyltransferase; MP, molecular profiling; NA, not available; Neg, negative; 1; PDGFRA, platelet-derived growth factor receptor alpha; PGP,P-glycoprotein; PgR, progesterone receptor; Pos, positive; RRM2B, ribonucleotide reductase M2 B; SPARC, secreted protein acidic and rich in cysteine; SSTR2, somatostatin receptor 2; TOPO1/TOP1, topoisomerase I; TOP2A/B, topoisomerase II alpha/beta; TS, thymidylate synthase; TUBB3, tubulin, beta 3 class III; VDR, vitamin D receptor; VEGFR2, vascular endothelial growth factor receptor; w.t., wild type.
